1. Home
  2. NUVB vs SPT Comparison

NUVB vs SPT Comparison

Compare NUVB & SPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • SPT
  • Stock Information
  • Founded
  • NUVB 2018
  • SPT 2010
  • Country
  • NUVB United States
  • SPT United States
  • Employees
  • NUVB N/A
  • SPT N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • SPT Computer Software: Prepackaged Software
  • Sector
  • NUVB Health Care
  • SPT Technology
  • Exchange
  • NUVB Nasdaq
  • SPT Nasdaq
  • Market Cap
  • NUVB 837.0M
  • SPT 799.3M
  • IPO Year
  • NUVB N/A
  • SPT 2019
  • Fundamental
  • Price
  • NUVB $2.75
  • SPT $14.11
  • Analyst Decision
  • NUVB Strong Buy
  • SPT Buy
  • Analyst Count
  • NUVB 6
  • SPT 11
  • Target Price
  • NUVB $8.00
  • SPT $27.73
  • AVG Volume (30 Days)
  • NUVB 4.6M
  • SPT 902.8K
  • Earning Date
  • NUVB 08-07-2025
  • SPT 08-06-2025
  • Dividend Yield
  • NUVB N/A
  • SPT N/A
  • EPS Growth
  • NUVB N/A
  • SPT N/A
  • EPS
  • NUVB N/A
  • SPT N/A
  • Revenue
  • NUVB $14,355,000.00
  • SPT $430,795,000.00
  • Revenue This Year
  • NUVB $98.78
  • SPT $12.33
  • Revenue Next Year
  • NUVB $489.71
  • SPT $11.83
  • P/E Ratio
  • NUVB N/A
  • SPT N/A
  • Revenue Growth
  • NUVB 900.35
  • SPT 14.79
  • 52 Week Low
  • NUVB $1.54
  • SPT $13.33
  • 52 Week High
  • NUVB $3.46
  • SPT $36.30
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 67.35
  • SPT 27.95
  • Support Level
  • NUVB $2.18
  • SPT $16.40
  • Resistance Level
  • NUVB $2.55
  • SPT $14.38
  • Average True Range (ATR)
  • NUVB 0.18
  • SPT 0.88
  • MACD
  • NUVB 0.03
  • SPT -0.21
  • Stochastic Oscillator
  • NUVB 82.48
  • SPT 12.62

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.

Share on Social Networks: